September 20th Biotech Update

Still a boring market in terms of news. The sector appears to have successfully defended the bottom end of its range but one could argue it done so simply by performing in-line with a strong broad market. Given the broader strength it would have been an awful signal to breakdown but regardless of the reason, […]

September 10 Biotech Update

There is nothing going on in the sector. No real news. No new deals. You would have thought that September would bring about some news but it seems like we are stuck in the summer pattern. It looks like that breakout failed its test and the next key to watch is what happens at 120 […]

October 4 Biotech Update

We got some news to talk about today and it just so happens to be some good news and some bad news. In both cases, the news is specific enough to a stock that I doubt either would have broader implications, which means the sector will continue its longer term trend higher (with obvious peaks […]

September 21 Biotech Update

The sector did get some momentum with the news yesterday but it still feels like a grind that is in a holding pattern, although clearly not like the broader market that has done nothing. There is nothing new today, which might give us a better sense if there is an underlying bid in the sector […]

September 20 Biotech Update

We are starting to get some meaningful data this week and while I suspect it will have some broader upside today, I will be curious to see if the sector moves and maintains a move. It seems to me that everyone is really wanting to see the AXON data and if any data is going […]

September 15 Biotech Update

It still looks to me that the sector is acting less like a sector and more like an aggregation of individual stocks. That is always true (it is not a stock market but a market of stocks) but usually there is a rising (or lowering) tide that raises (or lowers) all boats effect. I find […]

September 13 Biotech Update

The sector in general appears to be treading water at these levels but that seems to belie the larger moves under the surface. I think keeping these levels and having good news rewarded and bad news punished is a sign of the relatively healthy sector, especially heading into historically risky months for the market. 1. […]

September 1 Biotech Update

They say that the market never bottoms on a Friday and I wonder if the same is true of topping? The sector has clearly had a strong near term move and is due for a pause but would strength today be the near term top or is there more to go? Over the longer term […]

August 31 Biotech Update

The good news and move for the sector continues. In isolation the move higher seems a stretch in terms of the fundamental news that we have seen the past week. The news has been good but we have had weeks with better news and did not have this reaction. Clearly sentiment has changed in the […]

August 20 Biotech Update

Another slow news day with a more of the same market. What looked like a developing trend of strong small cap performance has morphed back into the run of the large caps. Perhaps that is simply a signal that we are entering into a stock pickers market as opposed to broad plays on sectors. In […]

Recent Option Activity (8/6 ~ 8/12)

The following stocks had recent and notable activity in their options: $INFI (8/6): 3,822 SEP 10.0 strike Puts were sold (stock at $9.98) for 0.45 or total proceeds of $171,990. This is a bullish/neutral strategy where the seller makes money as long as the stock settles above $9.55 by September expiration. $FOLD (8/12): 1,100 SEP […]

Upcoming WORLD symposium meeting

(with Jason Chew) Lysosomal Disease Network WORLD Symposium meeting The Lysosomal Disease Network (LDN) WORLD Symposium provides an interdisciplinary forum to explore and discuss specific areas of research and clinical interest related to lysosomal diseases. With regards to clinical data presentations, all of the important clinical data will be released on Friday, February 15th. Amicus […]

FOLD – Getting Ready For The New Uptrend

Amicus Therapeutics, Inc. (NASDAQ: FOLD) With FOLD on the move again, we wanted to look at how the stock is performing from a technical perspective , especially after Patrick’s report “FOLD – Bullish on Amicus Therapeutics” which highlighted the upcoming catalysts for this company. In particular, the top-line data from their Phase 3 study of […]

FOLD – Phase II Amigal Co-administration Update

Amicus Therapeutics released updated data Thursday for its chaperone molecule Amigal (migalastat) for Fabry disease at the American Society of Human Genetics (ASHG) Annual Meeting. Results looked good, continuing to build on positive data presented earlier this year. This study looks at the ability of Amigal to increase the activity of Enzyme Replacement Therapies (ERTs) […]

FOLD – Quick Take – Amigal P3 Monotherapy

Amicus Therapeutics is expected to unveil results from its Phase III registration trial for migalastat (Amigal) as monotherapy for the treatment of Fabry disease in the third quarter of this year. The study, if successful, will allow Amicus to file for marketing approval in the U.S. A separate global Phase III is also in progress. […]